184 related articles for article (PubMed ID: 35193817)
1. Adverse reactions and production of neutralizing anti-SARS-CoV-2 antibodies after ChAdOx1 COVID-19 vaccination: A cross-sectional study in a single center.
Jeong YJ; Kim YJ; Kim SH; Yoo J; Lee J; Lee S; Il Kim S
J Infect Public Health; 2022 Mar; 15(3):360-364. PubMed ID: 35193817
[TBL] [Abstract][Full Text] [Related]
2. A study on seroconversion following first & second doses of ChAdOx1 nCoV-19 vaccine in Central Kerala.
Varghese SM; Mateethra GC; George G; Chandran VS; John GM; Varghese LT; Mammen NK; Vinayak V
Indian J Med Res; 2022; 155(5&6):499-504. PubMed ID: 36348597
[TBL] [Abstract][Full Text] [Related]
3. Presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies Among Vietnamese Healthcare Workers by Dosing Interval for ChAdOx1 nCoV-19 Vaccine.
Vu DM; Vu DTB; Do TTT; Olmsted AE; Dao BH; Thai TT; Nguyen CL; Le NTT; Le TA; Bui HTT; Pham TN; Moore MR
Clin Infect Dis; 2022 Oct; 75(Suppl 2):S174-S181. PubMed ID: 35723271
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
[TBL] [Abstract][Full Text] [Related]
5. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions.
Lee SW; Moon JY; Lee SK; Lee H; Moon S; Chung SJ; Yeo Y; Park TS; Park DW; Kim TH; Sohn JW; Yoon HJ; Kim SH
Front Immunol; 2021; 12():779212. PubMed ID: 34899739
[TBL] [Abstract][Full Text] [Related]
6. Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals.
Patil R; Shanbhag S; Shankarkumar A; Madkaikar M
Indian J Med Res; 2022; 155(5&6):538-545. PubMed ID: 36124500
[TBL] [Abstract][Full Text] [Related]
7. Reactogenicity and Immunogenicity of the ChAdOx1 nCOV-19 Coronavirus Disease 2019 Vaccine in South Korean Healthcare Workers.
Hyun J; Park Y; Song YG; Han SH; Park SY; Kim SH; Park JS; Jeon SY; Lee HS; Lee KH
Yonsei Med J; 2022 Dec; 63(12):1078-1087. PubMed ID: 36444543
[TBL] [Abstract][Full Text] [Related]
8. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan.
Kang CM; Lee NY; Lin CH; Hsu YS; Chang YC; Chung MY; Lee YF; Tseng WP; Wu JL; Chen SY; Lu MC; Ko WC; Lee PI; Hsueh PR
J Clin Virol; 2022 Jun; 150-151():105156. PubMed ID: 35413588
[TBL] [Abstract][Full Text] [Related]
10. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
[TBL] [Abstract][Full Text] [Related]
11. Outcome after single dose of ChAdOx1 vaccine against SARS-CoV-2 infection at 16 weeks post-vaccination among healthy adults in Saudi Arabia.
Alghamdi A; Alsanea N; Alraey M; Joseph M; Aboud M; Almangour T; Alharbi W; Alhumidan H; Alanizi A; Al-Jedai A
Ann Saudi Med; 2022; 42(4):223-228. PubMed ID: 35933607
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
Front Immunol; 2022; 13():811020. PubMed ID: 35126395
[TBL] [Abstract][Full Text] [Related]
14. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
Özgür D; Tütüncü EE
Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
[TBL] [Abstract][Full Text] [Related]
15. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
[TBL] [Abstract][Full Text] [Related]
16. Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity.
Bae S; Ko JH; Choi JY; Park WJ; Lim SY; Ahn JY; Song KH; Lee KH; Song YG; Chan Kim Y; Park YS; Choi WS; Jeong HW; Kim SW; Kwon KT; Kang ES; Kim AR; Jang S; Kim B; Kim SS; Jang HC; Choi JY; Kim SH; Peck KR
Clin Microbiol Infect; 2022 Oct; 28(10):1390.e1-1390.e7. PubMed ID: 35598855
[TBL] [Abstract][Full Text] [Related]
17. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of R-FIND SARS-CoV-2 Neutralizing Antibody ELISA and FREND COVID-19 SP Rapid Fluorescence Immunoassay.
Yoo J; Kim YJ; Choi H; Lee J; Kim SH; Jeong YJ; Kim JS; Kim KH; Kim H; Lee S; Suh IB
Clin Lab; 2022 May; 68(5):. PubMed ID: 35536090
[TBL] [Abstract][Full Text] [Related]
19. Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers.
Jantarabenjakul W; Chantasrisawad N; Puthanakit T; Wacharapluesadee S; Hirankarn N; Ruenjaiman V; Paitoonpong L; Suwanpimolkul G; Torvorapanit P; Pradit R; Sophonphan J; Putcharoen O
Asian Pac J Allergy Immunol; 2022 Sep; 40(3):269-277. PubMed ID: 34717527
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Results of Five SARS-CoV-2 Antibody Assays before and after the First and Second ChAdOx1 nCoV-19 Vaccinations among Health Care Workers: a Prospective Multicenter Study.
Jeong S; Lee N; Lee SK; Cho EJ; Hyun J; Park MJ; Song W; Jung EJ; Woo H; Seo YB; Park JJ; Kim HS
J Clin Microbiol; 2021 Nov; 59(12):e0178821. PubMed ID: 34613799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]